Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2025

Conditions

Colon Cancer

Interventions

DRUG

Epigallocatechin gallate (EGCG)

Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).\*

Trial Locations (1)

UT Health San Antonio, San Antonio

All Listed Sponsors

lead

The University of Texas Health Science Center at San Antonio

OTHER